Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The Centers for Medicare and Medicaid Services (CMS) says about 8,247,000 people with Medicare Part D coverage use the ten drugs selected for price negotiation.

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle ...

Medicare has undergone several major changes since it launched in 1965. And now, with the passage of the Inflation Reduction Act of 2022, it's poised to change again, with several key ...

The economic policies outlined by the incoming Trump administration won’t cause a radical shift in inflation, former Federal Reserve Chairman Ben Bernanke said Saturday. “I agree Trump ...

Millions of Part D patients who rely on price-controlled drugs will see their out-of-pocket medication costs increase.

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...

The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department ...

Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish ...